European perspective of perampanel response in people with Intellectual Disability
dc.contributor.author | Allard, J | |
dc.contributor.author | Henley, W | |
dc.contributor.author | Snoeijen‐Schouwenaars, F | |
dc.contributor.author | van Ool, J | |
dc.contributor.author | Tan, I | |
dc.contributor.author | Schelhaas, HJ | |
dc.contributor.author | Majoie, MHJM | |
dc.contributor.author | Hudson, S | |
dc.contributor.author | McLean, B | |
dc.contributor.author | Shankar, R | |
dc.date.accessioned | 2020-05-11T07:40:18Z | |
dc.date.issued | 2020-05-08 | |
dc.description.abstract | Background Epilepsy prevalence is over 20% for those with ID. It is difficult to diagnose and treat and more likely to be treatment resistant. The evidence informing prescribing is sparse, particularly for new drugs such as Perampanel (PMP). Aims of the Study This study seeks to strengthen the research evidence regarding PMP for people with ID by pooling information from two isolated and separately conducted studies: the UK based Epilepsy Database Register (Ep‐ID) and the data from the Kempenhaeghe clinic in the Netherlands. Methods A single dataset of comparable data was created and analysed under agreement and supervision of a UK statistician. Results Seizure reduction within twelve months was evident in 62% of Dutch and 47% of UK patients. Retention rates were higher for those in the UK (P=0.01) and for patients with moderate to profound ID, whilst side effects were more prominent in the Dutch cohort. Conclusions Comparable rates of seizure reduction are in line with estimates for non‐ID patients, adding to the evidence suggesting that PMP has a similar impact on those with ID. Taking a European perspective and sharing data across centres can help strengthen the evidence for prescribing antiepileptic drugs in the ID population. | en_GB |
dc.description.sponsorship | Eisai UK | en_GB |
dc.identifier.citation | Published online 8 May 2020 | en_GB |
dc.identifier.doi | 10.1111/ane.13261 | |
dc.identifier.grantnumber | IIS –CFT-PER -03 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/120987 | |
dc.language.iso | en | en_GB |
dc.publisher | Wiley | en_GB |
dc.rights | © 2020 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | en_GB |
dc.subject | seizures | en_GB |
dc.subject | co morbidity | en_GB |
dc.subject | mental health | en_GB |
dc.subject | behavioral health | en_GB |
dc.subject | physical health | en_GB |
dc.subject | epilepsy | en_GB |
dc.subject | intellectual disability | en_GB |
dc.subject | UK Ep-ID Database Register | en_GB |
dc.subject | perampanel | en_GB |
dc.title | European perspective of perampanel response in people with Intellectual Disability | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2020-05-11T07:40:18Z | |
dc.identifier.issn | 0001-6314 | |
exeter.article-number | ane.13261 | en_GB |
dc.description | This is the final version. Available on open access from Wiley via the DOI in this record. | en_GB |
dc.identifier.journal | Acta Neurologica Scandinavica | en_GB |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | en_GB |
dcterms.dateAccepted | 2020-05-08 | |
rioxxterms.version | VoR | en_GB |
rioxxterms.licenseref.startdate | 2020-05-08 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2020-05-11T07:32:28Z | |
refterms.versionFCD | AM | |
refterms.dateFOA | 2020-05-29T15:11:55Z | |
refterms.panel | A | en_GB |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's licence is described as © 2020 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.